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Amino acid therapy in the treatment of experimental acute
renal failure in the rat
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Amino acid therapy in the treatment of experimental acute renal
failure in the rat. Rats injected with mercuric chloride, 1 mg/kg
body wt iv., or 50% glycerol, 10 mg/kg body wt i.m., were
treated with various amino acid regimens to determine whether
renal failure could be prevented or its course altered by such
therapy. In the first protocol, amino acids were infused in mas-
sive amounts beginning 30 hours after mercuric chloride injec-
tion. The second protocol used amino acids at approximately
one-third that rate beginning immediately after mercuric chloride
or glycerol injection and lasting until the animals' sacrifice 48
hours later. The dose was further reduced in a third study of
glycerol-induced acute renal failure. The last experiments used
only essential amino acids given at a dose reasonably consistent
with that used in clinical studies and continued for 5 days to as-
sess whether such treatment would accelerate the rate of recov-
ery of renal function. Rats given the largest doses of amino acids
had inordinately high BUN concentrations, and their mortality
rate greatly exceeded that of animals infused with equivalent vol-
umes of 19% or 5% dextrose solution (36% vs. 2%). The mean
creatinine concentration of myohemoglobinuric rats given amino
acids, 3.2 g/24 hours, continuously for 48 hours rose significantly
less than did that of glucose-infused controls. Of the 21 rats in
this group, 10 died before the end of the study, however, and it
seems likely (though unproven) that the lower mean serum
creatinine value obtained reflects the exclusion of the large per-
centage of animals dying in renal failure whereas only the least
affected were included in the 48-hour mean scoring. None of the
remaining four protocols provided any significant protection of
renal function, accelerated the rate of recovery from renal fail-
ure, or improved the survival rate of rats given amino acids after
an acute renal failure challenge, however. It is thus unclear
whether the lower serum creatinine concentration found in but
one of the five protocols truly represents partial protection of
renal function or instead reflects the death of the most severely
azotemic animals and the consequent inclusion of only those rats
with the least severe renal function impairment.
Inefficacité du traitement par les acides aminés de l'insuffisance
rénale aiguë expérimentale du rat. Des rats ont recu des injec-
tions i.v. de 1 mg/kg de chlorure de mercury ou intra-musculaires
de 10 mg/kg de glycerol 50% et ont été traités par divers regimes
d'acides aminés afin de savoir si l'insuffisance rénale peut étre
empêchée ou modifiée dans son evolution au moyen d'une telle
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thérapeutique. Dans le premier protocole les acides aminCs ont
éte perfusés en quantité importante a partir de Ia 30e heure après
l'ingestion de chlorure de mercury. Dans le second protocole les
acides aminés ont été utilisés a un debit réduit au tiers, en com-
mencant immédiatement après l'administration de chlorure de
mercury ou de glycerol. La dose d'acides aminés a encore etC
réduite dans une troisième étude de l'insuffisance rCnale aiguë
myohCmoglobinurique. Pour ces derniCres experiences seuls des
acides aminés essentiels a des doses semblables a celles utilisées
en clinique humaine ont Cté employés, pendant 5 jours, de facon
a établir si un tel traitement peut accélérer l'amélioration de Ia
fonction rénale. Les rats qui ont recu les doses les plus élevées
d'acides aminés avaient des concentrations d'urée sanguine plus
élevées qu'à l'ordinaire et leur mortalité a été supCrieure (36%
et 2%, respectivement) a celle des animaux qui ont recu des vol-
umes equivalents de solution de dextrose a 19 ou 5%. La concen-
tration moyenne de créatinine des rats myohémoglobinuriques
qui ont recu 3,2 g/24 heure d'acides aminés de facon continue
pendant 48 heures a augmenté significativement moms que celle
des contrôles recevant du glucose. Douze parmi les 21 rats de cc
groupe sont morts avant Ia fin de l'étude et il semble probable
(quoique non dCmontrC) que Ia crCatininCmie moyenne faible
reflCte l'exclusion de cette moyenne des animaux morts
d'insuffisance rCnale et l'inclusion des seuls animaux les moms
atteints. Aucun des quatre autres protocoles n'a permis de mon-
trer une protection significative de Ia fonction rénale, une accClé-
ration significative de Ia récupération, ou une amelioration de Ia
survie des rats qui ont recu des acides aminés après Ia creation
d'une insuffisance rénale aiguë.
Hyperalimentation with amino-acid-rich solu-
tions has been reported to greatly improve the sur-
vival rate of patients with acute renal failure of di-
verse etiologies [1, 2], and to shorten the duration of
renal insufficiency in patients with vasomotor ne-
phropathy [1]. Unfortunately, similar success has
not been obtained universally [3], and the proposi-
tion that amino-acid-supplemented hyperalimenta-
tion ought to be used widely in the treatment of this
syndrome would be strengthened if similar benefi-
cial effects could be domonstrated under controlled
laboratory conditions. Only one such study has ap-
peared in the literature [4]. We, therefore, have ex-
amined the effect of a variety of amino acid infusion
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regimens on mercury-induced and myohemoglob-
inuric acute renal failure in the rat.
Methods
Female Sprague-Dawley rats, each weighing 179
to 256 g, were kept in individual metabolic cages
and, except where indicated, allowed free access to
Purina© rat chow and water throughout the study.
Intravenous fluids, when appropriate to the pro-
tocol, were given through a PE-50 catheter inserted
into a jugular vein with the rat under ether anes-
thesia. The catheter was passed subcutaneously to
exit at the midback, where it passed through a pre-
weighed harness and 12-inch-long, V8-inch-O.D.
spring to exit from the top of the cage and terminate
in a swivel connector attached to a precision pump.
Fluids were administered through this catheter con-
tinuously thereafter with the animals awake and un-
restrained, the composition of the solutions varying
with the protocol involved. On terminating each ex-
periment, lissamine green solution was injected
through the jugular vein catheter, the chest was
opened, and placement of the catheter was checked
by the presence of dye in the heart. Dislocation of
the catheter disqualified the rat from the series (8 of
130 catheters).
Blood urea nitrogen (BUN) and serum creatinine
concentrations in the control and experimental peri-
ods were measured with an autoanalyzer. Several
previous studies in this laboratory have shown an
excellent correlation between serum creatinine con-
centration and inulin clearance in both mercuric
chloride and glycerol-induced acute renal failure [5—
8] (unpublished observations). Inulin clearances
thus were not determined in this study. Serum and
urinary electrolytes, when studied, were measured
using a flame photometer (IL), and osmolality was
measured with an osmometer (Advanced).
Data are presented as the mean SEM. Com-
parisons of means were made with Student's t test,
and differences in paired values were evaluated
with Fisher's paired t test [9].
The amino acid infusion protocols are summa-
rized in Table I.
Protocol 1. This protocol used the same mercuric
ion dose (1.0 mg/kg of body wt) and an amino acid
infusion very similar to that used previously by To-
back [4]. Prior to study, the animals were weighed,
and a 1-ml blood sample was taken for the measure-
ment of baseline BUN and serum creatinine con-
centration as well as for the determination of serum
sodium, potassium, and osmolality. Any abnormal-
ity in these parameters excluded the animal from
further experiments. Two days after baseline blood
drawing, the rats were reweighed, and 1.3 mg/kg
mercuric chloride (1.0mg of mercury per kg of body
wt) in 0.2 ml of saline was injected into the dorsal
tail vein. The rats were returned to their metabolic
cages, and their urine was collected quantitatively.
Approximately 28 hours after the mercuric chloride
injection, the animals were anesthetized with ether
and reweighed. A PE-50 jugular vein catheter was
inserted as above, and 0.6 ml of blood was drawn
for chemistry testing. The blood withdrawn was re-
placed with 3 ml of isotonic saline over the succeed-
ing 2 hours. Thereafter (30 hours after the acute re-
nal failure challenge), animals in group 1 (N = 18)
were given a solution containing FreAmine II (46
ml; McGaw Pharmaceutical Co., Glendale, Califor-
nia) and 50% dextrose (4 ml) through the jugular
vein catheter at a rate of 2.3 mllhour for the next 18
hours. The total amino acids given amounted to
3.28 g, and the osmolality of this and the 19% dex-
trose control solution was approximately 1,100
mOsm/kg H20. Animals in group 2 (N = 6) received
19% dextrose, and rats in group 3 (N = 6) were giv-
Table 1. Fluid and amino acids administered
Protocol Challenge
Amino acid
preparation8
Infusion Amino acids
Volume/time
mi/hr
Duration
days
Osmolality
mOms/kg/H20
Total
g/24 hr
Essential
g/24 hr
Nonessential
g/24 hr
I
2a
2b
3
4
HgCl2
HgCI2
Glycerol
Glycerol
Glycerol
FreAmine2
FreAmine2
FreAmine2
FreAmine2
Nephramine
2.33
1
1
1
1
0.75
2
2
2
5
1100
1100
1100
335
1100
3.28(18 hr)b
1.96
1.96
0.62
0.19
1.62 (18 hr)
0.97
0.97
0.31
0.19
1.66(18 hr)
0.99
0.99
0.31
0
a Amino acids in protocols I, 2a, 2b, and 4 were administered in 4% dextrose solution. Protocol 3 used 6.3% dextrose solution as the
vehicle, and protocol 4 used 19% dextrose. FreAmine 2 contains (g/dl): L-isOleUcifle, 0.59; L-leucine, 0.77; L-lysine, 0.62; methionine,
0.45; L-phenylalanine, 0.48; L-theonine, 0,34; L-tryptophan, 0.13; L-valine, 0.56; L-arginine, 0.31; L-histidine, 0.24; L-proline, 0.95; L-
serine, 0.50; L-glycine, 1.7; L-cysteine, < 0.02. Nephramine contains (g/dl): L-isoleucine, 0.56; L-leucine, 0.88; i-lysine, 0.64; L-methi-
onine, 0.88; L-phenylalanine, 0.88; L-threonine, 0.40; L-tryptophan, 0.20; L-valine, 0.65; L-alanine 0.6.
b 437 g/24 hr.
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en 5% dextrose solution (N = 6) without amino
acids, all at the same rate as that given to animals in
group 1. Animals in group 4 (N = 6) received no
intravenous infusions. All rats had free access to
food and water throughout the study. Forty-eight
hours after the mercuric chloride injection, the rats
were anesthetized and reweighed. Blood was then
removed from the vena cava for blood chemistry
determinations, and the placement of the venous
catheter was confirmed.
Protocol 2. To avoid the possibility that anes-
thesia and catheterization of the jugular vein them-
selves might affect adversely the renal function of
rats with established renal failure, we inserted the
venous catheter 2 days prior to onset of this study
and kept it patent by continuously infusing 0.18 ml!
hour of isotonic saline. Blood was drawn for base-
line biochemical studies, the animals were weighed,
and mercury, 1 mg/kg body wt, was given i.v. 2
days later (protocol 2a). Starting immediately after
mercuric chloride injection and continuing for the
next 48 hours, solutions identical with those used in
protocol 1 were infused at a rate of 1 ml!hour; food
and drinking water were allowed ad lib. Body
weight was followed serially, and 0.3 ml of tail vein
blood was obtained for the measurement of BUN
concentration 24 hours after mercury injection.
Forty-eight hours after mercuric chloride was ad-
ministered, the experiments were ended, and blood
was drawn for the measurement of serum elec-
trolytes, osmolality, creatinine, and BUN.
An identical protocol (2b) was followed for ani-
mals given 50% glycerol (10 mllkg of body wt, i.v.)
in place of mercury except that their water bottles
were removed for 12 hours prior to glycerol injec-
tion. These rats and their controls receiving 19%
dextrose or no infusion were allowed free access to
food and water for the remainder of the study.
Protocol 3. Acute renal failure was produced in
this protocol with 50% glycerol (10 mllkg of body
wt, i.m.), and the animals were handled in the same
manner as were the glycerol-injected rats in pro-
tocol 2. Here, however, the FreAmine and hyper-
tonic dextrose solutions were diluted threefold to
give an approximate osmolality of 335 mOsm!kg
H20, and infused at a rate of 1 mllhour for 48 hours.
Protocol 4. Nephramine© (McGaw Pharmaceuti-
cal Co., Glendale, California), a commercial prepa-
ration containing only essential amino acids, was
substituted for FreAmine in a subpopulation of 11
glycerol-injected rats and diluted 66-fo1d with 19%
dextrose to give a final amino acid load of 0.19 g!24
hours. Control animals received 19% dextrose solu-
tion, both solutions being given at a rate of I mll
hour, and the animals were allowed free access to
food and water. The experiment was allowed to
continue for 5 days after glycerol injection to deter-
mine whether this regimen, which more closely fol-
lows that used in man, would influence the in-
cidence and severity of renal insufficiency. Blood
samples were obtained for measurement of serum
sodium, potassium, creatinine, and BUN concen-
trations 1, 2, and 3 days later. Surviving animals
were sacrificed after 5 days, and blood chemistries
were obtained again.
Results
Protocol 1. The BUN and serum creatinine con-
centrations of all but 4(2 FreAmine, 2 control) of 36
animals in this protocol rose markedly in the 28-
hour period after mercuric chloride injection, and
no differences in means were observed between the
various study groups (P > 0.3 or above, Table 2).
Five of the animals receiving FreAmine and one rat
given 5% dextrose solution died before the study
was completed. 48 hours after injection, the mean
BUN concentration of the 13 surviving amino-acid-
infused rats was twice that at 24 hours (P <0.001)
and 81 to 91% higher than that of animals given an
equal volume of 5% dextrose solution or no fluid
infusion (P <0.05 or below). The wide difference in
mean BUN between rats treated with amino acid
and dextrose (262 [SE Mi 34 mg!dl) and rats treated
with 19% dextrose (167 23 mg/100 ml) was not
significant (1.0 > P > 0.05). The rise in serum
creatinine concentration throughout the study was
comparable in all four experimental groups (P >0.5
or above, Table 2); the urine volume of all groups
increased approximately twofold above that in the
control period (P < 0.001) despite the rise in serum
creatinine concentration. Treated as paired data, no
significant change was observed between the 28-
hour and 48-hour serum creatinine values of indi-
vidual rats (P > 0.2) in any of the four groups, al-
though considerable individual variation was ob-
served (Fig. 1). The serum osmolality of animals re-
ceiving the amino acid and dextrose solution rose
by one third (P < 0.01) between 28 and 48 hours
after the mercuric chloride injection, whereas that
of the remaining group was little different from the
immediate preinfusion value (Table 2). Serum so-
dium and potassium concentrations, at the time of
sacrifice, were comparable in all groups (P >0.30).
Protocol 2a. The results of experiments in which
mercuric-chloride-injected animals were infused
with FreAmine II or control solutions from the on-
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TabIe 2. Studies of rats receiving mercury (I mg/kg body wt): Protocol l
Infusion
Amino acid + dextrose 19% Dextrose 5% Dextrose None
(N = 18) (N = 6) (N = 6) (N = 6)
Body wt,g
Baseline 205 3 198 3 196 2 188 3
28hr 194 4 206 4 187 2 190 3
48hr 196 8(13) 220 8 183 10 179 5
BUN, mg/dl
Baseline 20 2 14 1 18 1 15 I
28hr 131 11 132 18 114 16 106 18
48hr 262 34(13) 167 23 137 30" 145 29b
Serum creatinine, mg/dl
Baseline 0.61 0.02 0.56 0.03 0.55 0.01 0.61 0.03
28hr 3.53 0.26 3.47 0.24 3.36 0.63 3.19 0.56
48hr 3.11 0.41(13) 4.16 0.39 2.74 0.52 3.84 0.98
Urine osmolality, mOs,n/kg H20
Baseline 1965 159 — — 1242 312
28hr 603 70 606 49 590 41 654 161
48hr 571 80(13) 359 39 307 49 580 163
Urine volume. ml
Baseline 9.1 1.1 11.0 2.6 — 11.0 2.6
Oto24hr 19.7 2.6 20.3 4.8 17.3 3.2 20.3 4.8
3Oto48hr 27.6 3.4(13) 14.8 3.0" 26.7 8.7 14.8 3.0"
Plasma osmolality, rnOsm/kg H20
Baseline 300 3(6) 297 3 299 2 301 2
28hr 309 6(18) 336 4 316 6 301 5
48hr 415 10(13) 346 18c 319 9' 346 II'
Deaths 5 0 0 0
Catheter failures 0 0 0 0
avalues represent the mean SEM. Numbers of samples are shown in parentheses. Baseline values for urine were obtained in the 24-
hr period prior to mercuric chloride injection.
bSignificantly different from amino-acid-infused series, P <0.05
'P <0.01 or below. All other differences in means are not significant (P > 0.05).
set of the renal failure challenge (protocol 2a) are
shown in Table 2 and Fig. 2. At this slower rate of
infusion, given from the time of the acute renal fail-
ure challenge, 3 of 14 mercury-injected rats given
amino acids, 2 of 7 given 19% dextrose, and 2 of 7
animals receiving no infusion developed minimal
renal insufficiency (serum creatinine less than twice
control) after the mercuric chloride injection. Four
amino-acid-treated rats died on the second experi-
mental day, and all rats given the control solutions
survived. Twenty-four hours after injection, the
mean BUN concentration of rats receiving the
amino acid and dextrose solution was far higher
than that of the two control groups (P <0.05 vs. no
infusion, Table 3). Forty-eight hours after the mer-
cury injection, the mean BUN concentration of the
10 surviving amino-acid-infused rats (235 [SEMI
48 mgldl) was considerably higher than that of the
other two groups (139 35 and 155 53 mgldl,
respectively), but the wide spread of data obviated
any statistically significant difference (P > 0.20).
The 48-hour serum creatinine concentration of the
surviving rats infused with amino acids was not dif-
ferent from that of the mercury-injected control
groups (P < 0.30 or above). Urine volume, plasma
osmolality, and change in body weight were com-
parable in all three groups over the 48-hour study
period (P > 0.10 or higher), as were serum sodium
and potassium concentrations (P > 0.30).
Protocol 2b. The results of studies on animals
given FreAmine and control solutions continuously
after glycerol injection are given in Table 4 and Fig.
2. The mean serum creatinine concentration of S of
21 rats given continuous infusions of FreAmine and
dextrose after glycerol injection increased less than
twofold in 48 hours (Fig. 2), but 10 rats in this group
died within the study period, and their terminal
serum creatinine concentrations are unknown.
There were two catheter failures. Of 11 rats receiv-
ing 19% dextrose solution, 4 had only minor eleva-
tions of serum creatinine (Fig. 2), 1 died, and I had
catheter failure. The mean 24-hour BUN concentra-
tion of rats given amino acids (222 17 mg/dl) was
almost twice that of animals receiving 19% dextrose
(P < 0.01), but statistically equivalent to the 173
19 mgldl value of noninfused rats (P > 0.10), all of
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480 48
Time, hours
Fig. 2. Protocols 2 and 3: The serum creati nine concentration
change 48 hr after ,nercury (upper) and glycerol (lower) injected
rats were continuously infused with hypertonic FreA mine or con-
trol solutions after their acute renal failure challenge. Symbols
applied to controls have the same meaning as in Fig. 1. Values
for 4 mercury-injected rats, 10 myohemoglobinuric rats, and I
control animal that died prior to 48-hr creatinine concentration
measurement are omitted.
body weight, BUN, and serum creatinine concen-
trations indistinguishable from their counterparts
given the same volume of dextrose alone, P > 0.2 or
higher (Table 5 and Fig. 3). Their mean 48-hour
serum creatinine concentration of 4.28 0.65 mgldl
was significantly higher (P < 0.01) than that of the
surviving animals receiving hypertonic FreAmine
solution in protocol 2b, but not different from that
obtained with isosmolal FreAmine solution (P >
0.4) in protocol 3. Four of eleven rats given Nephra-
mine and five of nine animals receiving 19% dex-
trose solution died in the 5-day study period (Table
5), but none died in the first 46 hours of renal fail-
ure. The course of serum creatinine change, shown
in Fig. 4, was not discernibly different in the 2 ex-
perimental groups. Amino acid treatment evidently
did not accelerate the speed or recovery of renal
function (Fig. 3).
Freamine Controls Freamine Controls
a,C
C
8
C,
E
a,U,
- I
48 28 48
C,C
C
C,
E
=
C,U,
7.
6
5.
11"
28
Time, hours
Fig. 1. Protocol 1: The serum creatinine concentration change of
mercury-injected rats given 3.3 g of essential and nonessential
amino acids in 42 ml of 19% dextrose solution between 30 and 48
hours after injection of mercuric chloride (1 mg/kg body wt, i.v.).
Asterisks represent 28-hr creatinine values of the 5 animals that
died during the infusion period. Among controls, triangles de-
note infusion with 19% dextrose solution, closed circles 5% dex-
trose, and open circles no infusion at all.
which survived the study. The mean 48-hour serum
creatinine concentration of the 9 dextrose infused
survivors (3.29 0.177 mgldl) proved not to be sig-
nificantly different from the 1.81 0.46 mgldl value
of the 10 surviving animals given amino acids (P >
0.1). No differences in body weight change, plasma
osmolality, urine volume, or serum sodium and po-
tassium concentrations were found between study
groups (P > 0.1 or above).
Protocol 3. The study parameters of rats given
335 mOsmar amino acid and dextrose solution after
glycerol injection are included in Table 4. Apart
from a significantly lower mean 24-hour BUN con-
centration than that found in glycerol-injected rats
in protocol 2b (153 11 vs. 222 17 mg/dl, P <
0.05), all values were statistically indistinguishable
from those of surviving glycerol-injected rats given
hypertonic amino acid solutions (P > 0.10 or high-
er). No animals in this series died.
Protocol 4. Rats given 0.19 g of essential amino
acids in 24 ml of 19% dextrose solution daily for 5
days after i.m. glycerol injection had changes in
2
Amino acid therapy of acute rena/failure 19
Discussion
The death rate associated with vasomotor ne-
phropathy (acute renal failure, acute tubular necro-
sis) has remained tragically high despite the advent
of early dialysis and an enlarged antibiotic arma-
mentarium. New modes of therapy are clearly
needed. Abel et al [1] have reported an increased
survival rate and a rapid return of renal function in
randomly selected patients with this syndrome giv-
en essential amino acids and hypertonic dextrose
solution parenterally. Lower mortality rates have
also been reported in another large, but uncon-
trolled, study using amino acid infusions [10], and
are suggested in some smaller series of cases [11—13].
The largest uncontrolled study, however, also pub-
lished by Abel et al [14], found an overall mortality
rate in amino-acid-treated patients that was not any
better than that of untreated patients in their earlier
report. Determining the value of agents that are not
universally efficacious in the treatment of vasomo-
tor nephropathy is made very difficult in the clinical
situation because of the number of uncontrollable
(and often unrecognizable) variables inherent to se-
riously ill patients with this syndrome. If greatly im-
proved survival rates and a shortened duration of
renal insufficiency could be demonstrated under
closely controlled laboratory conditions, however,
more widespread use of hyperalimentation with
amino-acid-rich solutions should be seriously enter-
tained despite the attendant risks [15]. Recently,
Toback [4] reported that rats given mercuric ion (1
mg/kg of body wt) exhibited a 12-fold rise in serum
creatinine concentration 48 hours later if untreated.
Although their renal histologic abnormalities were
comparable to those of untreated, mercuric-chlo-
ride-injected animals, counterparts given 3.9 g of
amino acids in 50 ml of dextrose solution between
30 and 48 hours after mercuric chloride injection ex-
perienced only a two-fold creatinine rise. As shown
in the present study, this dose of mercury typically
causes severe renal failure well within 24 hours of
injection. It would be assumed, therefore, that, hav-
ing started the amino acid infusions 30 hours after
mercury injection and finding a very modestly in-
creased serum creatinine concentration 18 hours
later, such therapy had largely reversed previously
established renal failure. Renal failure does not al-
ways follow injection of this dose of mercury, how-
Table 3. Studies of rats receiving mercury (1 mg/kg body wt): Protocol 2aa
Infusion
Amino acid + dextrose 19% Dextrose None
(N = 14) (N = 7) (N = 7)
Body wt,g
Baseline 205 5 199 6 209 5
24hr 205 5 192 5 199 4
48hr 192 5(10) 184 9 188 5
BUN, mg/dl
Baseline 22 1 26 2 24 1
24hr 187 22 61 l4c 100 27b
48hr 235 48(10) 139 35 155 53
Serum creatinine, mg/dl
Baseline 0.42 0.02 0.55 0.04 0.40 0.06
48hr 2.36 0.43(10) 3.24 1.03 2.59 0.70
Urine osmolality, mOsm/kg H20
Baseline 1790 142 2020 258
24hr 503 42 467 55
48hr 478 59(10) 415 71
Urine volume, ml
Baseline 16.6 1.1 12.4 1.4 13.0 1.1
24 hr 34.3 4.1 31.1 5.7 20.1 4.7
48hr 29.3 7.1(10) 31.1 5.1 17.1 5.6(5)
Plasma osmolality, mOsm/kg H20
Baseline 303 I 308 2 312 55
48hr 364 14(10) 338 8 339 14(5)
Deaths 4 0 0
Catheter failures 0 0 0
Values represent mean SEM. Numbers of samples are shown in parentheses. Baseline values for urine were obtained in the 24 hours
prior to mercuric chloride injection.
b Statistically different from corresponding amino acid infused rats, P < 0.05.
<0.01. All other differences in means are not significant (P > 0.05 or above).
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Table 4. Studies of rats receiving 50% glycerol (per kilogram body wt): Protocols 2 and 3
Infusion
Amino acid + dextrose
Isotonic
Hypertonic (Protocol 3) 19% Dextrose None(N=2I) (N=6) (N=ll) (N=7)
Body wt,g
Baseline 197 3 205 5 198 7 199 8
24 hr 209 4(20) 232 17 203 5 200 7
48hr 189 6(9) 200 5 191 9(9) 186 8
BUN, mg/dl
Baseline 26 1 24 2 22 7 24 3
24hr 222 17(20) 153 Ii" 124 26' 173 19
48hr 147 43(9) 229 41 133 27(9) 257 33
Serum creatinine, mg/dl
Baseline 0,51 .03 0.44 0.02 0.44 0.03 0.48 0.03
48hr 1.81 0.46(9) 3,55 058b 3.29 0.77(9) 6.43 0.89
Urine osmolality, ,nOs,n/kg
Baseline 2303 90 1489 l08 2425 309 2432 295
24hr 791 71(19) 612 84 747 103 1081 550(6)
48hr 682 85(9) 462 58 447 60(9)b 381 77(6)b
Urine volume ml
Baseline 3.9 0.3 5.8 0,9b 3.4 0.7 3.6 0.5
24hr 13.6 2.6(20) 17.3 4.7 15.9 3.6 6.7 4.3
48hr 26.5 5.8(9) 35.8 10.2 25.0 3.6(9) 16.6 5.1
Plasma osmolality, mOsmlkg H20
Baseline 319 3 — 326 6 321 11
48hr 368 17(9) — 349 13(9) 38! 10
Deaths 10 0 1 0
Catheter failures 2 0 I 0
Values represent mean SEM. Numbers of samples are shown in parentheses. Baseline values for urine were obtained in the 24 hours
prior to glycerol injection.
Statistically different from corresponding rats infused with hypertonic amino acids, P < 0.05; P <0.01. Serum creatinine (48 hr) of
noninfused rats was higher than in all other corresponding groups (P < 0.02 or below). All other differences in mean values are not
significant, P > 0.05.
ever; indeed, seven of the control animals given the
same amount of mercuric chloride in the present
study developed very mild or no renal failure (Figs.
1 and 2). Benefits found in the earlier experiments
[4] would have been more compelling, therefore, if
the rats' renal function had been assessed prior to
starting treatment.
In the present study, we have attempted to deter-
mine the benefits offered by a variety of amino acid
infusion regimens in two well-established renal fail-
ure models. The first study, designed to confirm To-
back's earlier results [4], used the same dose and
route of mercury administration and a comparable
volume of an identical FreAmine solution. The re-
search plan was modified in that female rats were
used, the animals were unrestrained and had free
access to food and water throughout, an additional
control study group was given an isovolemic in-
fusion of 5 gIdl dextrose solution, blood for the de-
termination of BUN and serum creatinine concen-
tration of each animal subjected to mercuric chlo-
ride injection was obtained prior to starting the
infusion, and an autoanalyzer technique, rather
than the method of Hare [16], was used for serum
creatinine measurement. Several prior studies have
shown a close correlation between BUN, serum
creatinine concentration, and inulin clearance in
both mercury- and glycerol-induced renal failure [5—
8] (unpublished data). Here, because of the likeli-
hood that the nitrogen load might unduly influence
BUN values, serum creatinine concentration was
used as the indicator of renal function. Judging from
the mean rise in serum creatinine concentration, at
least, the amino acid infusion regimen offered no
protection. We cannot explain the difference be-
tween our experimental results and those pre-
viously published [4], but are at least assured by
measurements of BUN and serum creatinine con-
centrations 28 hours after mercury injections that
most animals receiving amino acids and control so-
lutions in the present study had renal failure before
the infusions were begun.
In this series of experiments, as in the study we
were repeating [4], over 40 ml of a highly concen-
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trated fluid (a volume approximating the rats' total
extracellular space) was infused into rats with renal
failure in an 18-hour period. Such treatment might
well mask the prophylactic value of amino acids in-
fused in lesser amounts. The opportunity to observe
protection of renal function also might have been
better if amino acid infusions had been begun imme-
diately after the mercuric chloride injection, if the
trauma of the insertion of the jugular vein catheter
with its attendent anesthesia were not undertaken
when the rats were frankly azotemic, and if a less
extreme volume of fluid were infused. In the next
study, therefore, venous catheters were placed in
the rats 2 days before injecting either mercury or
glycerol, and the volume of blood drawn after 24
hours of renal failure was minimized by omitting
measurements of serum creatinine. The same ex-
perimental and control solutions used in the first
protocol were infused immediately after the renal
failure challenge, but at approximately one third the
rate (1 mllhr). An additional series of experiments
(protocol 3) used an isotonic amino acid and dex-
trose solution containing one-third the amino acid
load but with the same volume as in protocol 2.
Nephramine(N=l1) 19% Dextrose(N=9)
Body wt,g
Baseline 229 6 232 8
Day! 230 7 234 9
Day2 226 8 227 II
Day3 224 9(!0) 225 !4
DayS 190 11(7) 195 7
BUN, mgldl
Baseline 24 2 22 2
Day! !l4 13 130 18
Day2 171 24 196 25(8)
Day 3 185 33(10) 205 42(7)
Days 174 50(7) 100 32(4)
Serum creatinine,
mg/dl
Baseline 0.54 0.02 0.55 0.03
Day! 3.00 0.42 3.42 0.39
Day2 4.28 0.64 5.25 0.55(8)
Day3 4.64 0.77(!0) 5.33 0.89(7)
DayS 3.95 1.21(7) 3.14 0.85(4)
Deaths
Dayl 0 0
Day2 0 1
Day3 ! I
Day4 2 2
Days i I
As manifested by the mean rise in serum creati-
nine concentration, the well-established ameliorat-
ing effect of simple volume expansion on myo-
hemoglobinuric renal failure was again evident, rats
given amino acids and dextrose alike faring better
than animals given no infusions. The renal function
of amino-acid-treated rats was not significantly bet-
ter than control in three of these four protocols us-
ing both essential and nonessential amino acids or
in rats treated with Nephramine. In one protocol,
however, that using massive hypertonic amino acid
therapy in myohemoglobinuric rats, the serum
creatinine concentration was clearly lower than that
of the controls. Why this particular group should
have been partially protected while four other
amino-acid-treated groups were not is hard to ex-
plain. Of the 21 rats in the "protected" group, 10
died in the 48-hour time course of the study, and the
mean serum creatinine concentration given reflects
only values obtained in the survivors. Blood was
not drawn postmortem from most of the rats that
died, and it is unknown whether their terminal
creatinine concentrations were higher or lower than
those of the survivors. It seems, however, that ani-
mals with the poorest renal function would be at
highest risk of death when given a massive nitrogen
Nephramine Dextrose
a,C
C
a,
U
E
a,U,
4 50
Time, day
Fig. 3. Protocol 4: Time course of serum creatinine change of
rats given 0.19 g/24 hr of essential amino acids in 19% dextrose
solution over a 5-day period co,npared with values obtained in
rats given an equal volume (1 mllhr) of 19% dextrose solu-
lion alone. Asterisks reflect the last serum creatinine concentra-
tion measured prior to death, The triangle represents an animal
whose jugular vein catheter had become dislodged on the second
study day.
Table 5. Serial studies of myohemoglobinuric rats given
Nephramine or 19% dextrosea
a Values represent the mean SEM. Numbers of samples are
shown in parenthese. No statistically significant difference in any
parameter was evident in the two study groups (P > 0.10 or
higher).
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and fixed acid load and that animals with the best
maintained renal function would be most likely to
survive. Thus, whereas the lower mean serum
creatinine concentration obtained in this singular
protocol might truly represent protection imparted
by amino acid infusions, it seems equally possible
that the result reflects bias introduced by the death
of the rats with the most severe renal dysfunction.
This point is, however, unsettled.
Amino acid infusions had a markedly adverse ef-
fect on BUN concentration in both early protocols.
This presumably was due to the very large nitrogen
load given, because the BUN rise in protocol 1 was
far out of proportion to the change in serum creati-
nine concentration, and the degree of azotomia ob-
served in protocol 2 greatly exceeded that in pro-
tocols 3 and 4 where much smaller amounts of
amino acids were used. In all, 19 of 53 rats given
hypertonic amino acid solutions died, but all but I
of 50 animals given control or no infusion survived.
Whether the marked azotemia found in the early
protocols greatly influenced the inordinately high
mortality rate is problematic, because the actual
cause of death has not been studied formally. Be-
cause control animals received a comparable vol-
ume of equally hyperosmolal dextrose solution
through indwelling cannulae, however, the dif-
ference in mortality rates between groups would ap-
pear to relate solely to the amino acid content of the
infusate. In the first protocol, the amino acid load
approached the LD50 reported for rats by Gullino et
al [17]. Extrapolated to a 70-kg human, animals in
this series received the equivalent of 1 kg of amino
acids in a mere 18-hour period, and these amino
acids would have served as precursors for no less
than 700 mEq of hydrogen ion [18]. The smaller
amino acid load given in protocol 2 still provided
very substantial amounts of amino acids and was
associated with a high mortality rate. Autopsy ex-
aminations of two mercury-injected rats that died
under observation after 40 to 48 hours of FreAmine
infusion and four others that were sacrificed at the
end of 48 hours when seemingly in extremis re-
vealed normal lungs. No abscesses were found, and
blood cultures of these animals failed to grow any
pathogenic bacteria or fungi after 2 weeks' in-
cubation. A septic death seems unlikely in these an-
imals, at least. Serum potassium concentrations ob-
tained 24 hours after the onset of acute renal failure
did not serve to predict which animals would die in
the subsequent 24 hours (P > 0.4). Serum elec-
trolytes could not be measured postmortem, but oc-
casional survivors (both control and experimental)
had extremely high serum potassium concentra-
tions (> 8.5 mEq/liter). Rapidly developing, unde-
tected hyperkalemia thus could possibly account
for some of the deaths, particularly in view of the
acid load given. Hypokalemia (< 3.5 mEq/liter) was
not observed in any animal.
The final portion of this study was designed to
determine whether essential amino acids infused at
reasonable doses over a 5-day period would accel-
erate the rate of recovery of renal function, as sug-
gested by Abel et al [1] to occur in man. As shown
in Fig. 3 and Table 5, the course of renal dysfunc-
tion of myohemoglobinuric rats treated in this man-
ner was not different from that of controls. Of the 11
rats given Nephramine, 3 did develop very mild re-
nal failure (1 of these experienced catheter failure
on the second day), but, as shown by the controls in
Fig. 2b and past experience [19], the degree of renal
failure expected in this model is quite variable from
rat to rat. Because the remaining 8 Nephramine-
treated animals behaved very much like their dex-
trose-infused controls, no benefit can be attributed
to Nephramine therapy in these experiments. With
this dose of amino acids, as with the reduced amino
acid load used in protocol 3, the high mortality rate
seen early in myohemoglobinuric rats given large
amounts of FreAmine was obviated. Almost equal
numbers of treated and control rats died in the
course of the 5-day study period, the number of
deaths being consonant with past experience with
this model. Thus, neither benefit nor harm appeared
to result from prolonged Nephramine infusions in
these experiments.
Conclusion. We are unable to demonstrate a consis-
tent prophylactic effect, an abbreviated course, or
an improved survival when various amino acid doses
are infused into rats with myohemoglobinuric or
mercury-induced acute renal failure. These obser-
vations, however, cannot necessarily be extrapolat-
ed to the human situation.
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